This message was sent to ##Email##
Get your Family Doctor of the Day (FDOD) volunteer date on your calendar early and get first pick on dates and get it crossed off your to-do-list now! The 2020 legislative session will be here before you know it! We invite all of our active members and residents with a Kansas license, to serve as the FDOD at the Statehouse during the legislative session.
FDOD is a volunteer program organized by the Kansas Academy of Family Physicians, in which KAFP provides for a family physician to be present at the Statehouse each day during the legislative session. KAFP relies on its trusted membership to volunteer to serve as FDOD.
The FDOD program is an opportunity to network in Topeka, learn about the legislative process, perhaps attend part of a session or committee, and provide a much-appreciated service to legislators on behalf of KAFP.
Volunteers assist legislators and their staff with health needs that may arise throughout the day. Checking blood pressure, distributing ibuprofen, examining sore throats: the health issues are mainly minor health needs, with a few more serious ailments during the year. The legislators are grateful for the program and it definitely puts family medicine in a favorable light!
FDOD volunteers report to the Capitol Building in Topeka at 9:00 a.m. and stay until 3:00 p.m. taking care of legislators, staff and sometimes even visitors who need medical attention.
Thank you for your consideration of taking a day to volunteer for this important program.
The Annals of Family Medicine Special Supplement: Lessons From Practice Transformation is now available. It includes editorials, original research, research briefs, special reports and innovations in Primary Care.
The AAFP encourages members, especially those serving a significant number of women of childbearing age, to apply for the Alcohol Screening and Brief Intervention (SBI) Office Champions Project. The project, which will accept up to 25 family medicine practices, aims to increase the use of alcohol SBI within primary care settings, utilizing the office champions model. Applications are due September 20, 2019. Physicians who complete this quality improvement project also will receive Part IV maintenance of certification credit.
Learn more and apply today! Contact Reshana Peterson at RPeterson@aafp.org or 913-906-6103 with questions.
The Centers for Disease Control and Prevention (CDC) has issued a Health Advisory for Severe Pulmonary Disease Associated with Using E-Cigarette Products. The health advisory provides background information and recommendations for clinicians, public health officials, and the public based on currently available information. Below are recommendations for you from the CDC. Please read the CDC Health Advisory in its entirety.
Recommendations for Clinicians
1. Report cases of severe pulmonary disease of unclear etiology and a history of e-cigarette product use within the past 90 days to your state or local health department. Reporting of cases may help CDC and state health departments determine the cause or causes of these pulmonary illnesses.
2. Ask all patients who report e-cigarette product use within the last 90 days about signs and symptoms of pulmonary illness.
3. If e-cigarette product use is suspected as a possible etiology of a patient's severe pulmonary disease, obtain detailed history regarding:
4. Determine if any remaining product, including devices and liquids, are available for testing. Testing can be coordinated with the local or state health departments.
- Substance(s) used: nicotine, cannabinoids (e.g., marijuana, THC, THC concentrates, CBD, CBD oil, synthetic cannabinoids [e.g., K2 or spice], hash oil, Dank vapes), flavors, or other substances
- Substance source(s): commercially available liquids (i.e., bottles, cartridges, or pods), homemade liquids, and re-use of old cartridges or pods with homemade or commercially bought liquids
- Device(s) used: manufacturer; brand name; product name; model; serial number of the product, device, or e-liquid; if the device can be customized by the user; and any product modifications by the user (e.g., exposure of the atomizer or heating coil)
- Where the product(s) were purchased
- Method of substance use: aerosolization, dabbing, or dripping
- Other potential cases: sharing e-cigarette products (devices, liquids, refill pods, or cartridges) with others
5. Consider all possible causes of illness in patients reporting respiratory and gastrointestinal symptoms and of e-cigarette product use. Evaluate and treat for other possible causes of illness (e.g., infectious, rheumatologic, neoplastic) as clinically indicated. Consider consultation with specialists (pulmonary, infectious disease, critical care, medical toxicology) as appropriate.
6. Clinical improvement of patients with severe pulmonary disease associated with e-cigarette use has been reported with the use of corticosteroids. The decision to use corticosteroids should be made on a case-by-case basis based on risks and benefits and the likelihood of other etiologies.
7. Lipoid pneumonia associated with inhalation of lipids in aerosols generated by e-cigarettes has been reported based on the detection of lipid-laden alveolar macrophages obtained by bronchoalveolar lavage (BAL) and lipid staining (e.g., oil red O). The decision about whether to perform a BAL should be based on individual clinical circumstances.
8. Lung biopsies have been performed on some patients. If a lung biopsy is obtained, lipid staining may be considered during pathologic examination, and is best performed on fresh tissue. Routine pathology tissue processing (including formalin-fixation and paraffin-embedding) can remove lipids. Conducting routine tissue processing and histopathologic evaluation is still important. Consider consultation with specialists in pulmonary medicine and pathology to help inform any evaluation plan.
9. Patients who have received treatment for severe pulmonary disease related to e-cigarette product use should undergo follow-up evaluation as clinically indicated to monitor pulmonary function.
Register for the KAFP-Foundation Let’s Move, Kansas 5K Run/Walk by Friday, Sept. 13 for the best price. The adult pricing goes up on Sept. 14, 2019. Join us on Saturday, Oct. 19 at Sedgwick County Park in Wichita. All proceeds benefit the KAFP-Foundation.
Children / Youth 17 & under:
- 5 Mile Walk: $20 for all participants 17 and under
- 5K timed race: Adult pricing applies for participants 17 and under
Invite your co-workers, friends and family to register as a team for the Let’s Move, Kansas 5K Run/Walk and get $3.00 off per registrant. The largest team will receive a team trophy! Visit www.LetsMoveKansas.com to see a listing of teams to join! It is a great way to support the Foundation’s programs for residents and students while living a healthy lifestyle and sharing a great day with your friends, family and colleagues!
- August 20 – September 13: $35
- September 14 – October 4: $40
- October 5 – October 11: $45
- October 19 – Register Onsite: $50
Residents and medical students can use the discount code STURES19 for an additional $5.00 off.
Sponsorship opportunities close Saturday, Aug. 31. Act now if your hospital, clinic or company is interested in being a sponsor for this event, click here for more information.
Presenting sponsor, KU School of Medicine-Wichita
Media sponsor, KMUW Wichita 89.1
Platinum sponsors, Grene Vision Group and Wichita Surgical Specialists
Gold sponsor, Advanced Physical Therapy, Blue Cross Blue Shield of Kansas, Premier Property Management and West Wichita Family Physicians, PA
Silver sponsor, Wichita Urology
Bronze sponsors, Post Rock Family Medicine and Wichita Marriott
If you cannot participate in the race on Oct. 19, the KAFP-Foundation would greatly appreciate a donation to support residents and students. Give today. The mission of the KAFP-Foundation is to promote the philosophy of family medicine, research and education of Kansas family physicians.
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063